HE4 in the evaluation of tumor load and prognostic stratification of high grade serous ovarian carcinoma

Show full item record



Permalink

http://hdl.handle.net/10138/325932

Citation

Salminen , L , Gidwani , K , Grenman , S , Carpen , O , Hietanen , S , Pettersson , K , Huhtinen , K & Hynninen , J 2020 , ' HE4 in the evaluation of tumor load and prognostic stratification of high grade serous ovarian carcinoma ' , Acta Oncologica , vol. 59 , no. 12 , pp. 1461-1468 . https://doi.org/10.1080/0284186X.2020.1827157

Title: HE4 in the evaluation of tumor load and prognostic stratification of high grade serous ovarian carcinoma
Author: Salminen, Liina; Gidwani, Kamlesh; Grenman, Seija; Carpen, Olli; Hietanen, Sakari; Pettersson, Kim; Huhtinen, Kaisa; Hynninen, Johanna
Contributor organization: HUSLAB
Precision Cancer Pathology
Department of Pathology
Olli Mikael Carpen / Principal Investigator
Medicum
Research Program in Systems Oncology
University of Helsinki
Helsinki University Hospital Area
Date: 2020-12-01
Language: eng
Number of pages: 8
Belongs to series: Acta Oncologica
ISSN: 0284-186X
DOI: https://doi.org/10.1080/0284186X.2020.1827157
URI: http://hdl.handle.net/10138/325932
Abstract: Objective Human epididymis protein 4 (HE4) is a validated, complementary biomarker to cancer antigen 125 (CA125) for high grade serous ovarian carcinoma (HGSC). Currently, there are insufficient data on the utility of longitudinal HE4 measurement during HGSC treatment and follow up. We set to provide a comprehensive analysis on the kinetics and prognostic performance of HE4 with serial measurements during HGSC treatment and follow up. Methods This prospective study included 143 patients with advanced HGSC (ClinicalTrials.gov identifier: NCT01276574). Serum CA125 and HE4 were measured at baseline, before each cycle of chemotherapy and during follow up until first progression. Baseline biomarker values were compared to the tumor load assessed during surgery and to residual disease. Biomarker nadir values and concentrations at progression were correlated to survival. Results The baseline HE4 concentration distinguished patients with a high tumor load from patients with a low tumor load assessed during surgery (p
Subject: High grade serous ovarian carcinoma
biomarkers
HE4
CA125
prognostic marker
PREOPERATIVE SERUM CA-125
PROTEIN 4 HE-4
CANCER
CYTOREDUCTION
PREDICT
PROGRESSION
BIOMARKERS
GUIDELINES
3122 Cancers
Peer reviewed: Yes
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
Salminen_HE4_in ... us_ovarian_carcinoma_1.pdf 1.905Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record